title: Thrombophilia and fetal growth restriction.
abstract: OBJECTIVE
  Genetic thrombophilia may represent a new risk factor for obstetrical complications. The aim of the study was to determine which subgroups may be associated with genetic thrombophilia for small for gestational age infants (SGA).
  
  
  METHODS
  A case-control study was performed in three different maternity wards in Normandy. Cases (n=203) were women who had pregnancies complicated by unexplained SGA infants defined as a birth weight below the 3rd centile and control subjects (n=203) were women who had infants with birth weight > or =10th centile. Patients were tested in the immediate postpartum period and 2 months later for factor V Leiden mutation, and prothrombin 20210A mutation. Frequencies of these mutations were observed in different subgroups of SGA infants depending on pregnancy or neonatal outcomes usually associated with intrauterine growth restriction (IUGR), and were then compared with the overall prevalence for these mutations detected in the control group.
  
  
  RESULTS
  Prevalences for factor V Leiden mutation (or=2.58; 95% confidence interval: 0.83-8.04), prothrombin 20210A mutation (or=2.03; 95% confidence interval: 0.51-8.01), were comparable between cases and controls (4.9% versus 1.9% and 2.9% versus 1.4%, respectively). Frequencies for these two polymorphisms significantly increased in subgroups of SGA infants with a normal Pourcelot index (13/133 versus 7/203; P=0.04), a gestational age > or =37 weeks of gestation (15/143 versus 7/203; P=0.01), a vaginal delivery (11/117 versus 7/203; P=0.04), a birth weight > or =2000 g (12/121 versus 7/203; P=0.03), no admission to paediatric ward (11/116 versus 7/203; P=0.01), a low Ponderal index <2.5(e) centile (6/45 versus 7/203; P=0.04), and normal head circumference >10th centile (7/53 versus 7/203; P=0.01) in comparison with the control group.
  
  
  CONCLUSIONS
  An association was found between polymorphisms for factor V Leiden and prothrombin, and asymmetrical intrauterine growth restriction with immediate favourable neonatal outcomes.
authors.affiliation: Department of Obstetrics and Gynaecology, Clinique Gynécologique et Obstétricale. CHU, Charles Nicolle. 1, rue de Germont, Rouen University Hospital, Rouen, France. ericverspyck@chu-rouen.fr
authors.forename: E
authors.initials: E
authors.lastname: Verspyck
authors.forename: J Y
authors.initials: JY
authors.lastname: Borg
authors.forename: V
authors.initials: V
authors.lastname: Le Cam-Duchez
authors.forename: F
authors.initials: F
authors.lastname: Goffinet
authors.forename: S
authors.initials: S
authors.lastname: Degré
authors.forename: P
authors.initials: P
authors.lastname: Fournet
authors.forename: L
authors.initials: L
authors.lastname: Marpeau
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005165:Factor V / Q000235:genetics; D005260:Female; D005315:Fetal Diseases / Q000453:epidemiology* / Q000235:genetics; D005317:Fetal Growth Retardation / Q000453:epidemiology* / Q000235:genetics; D005602:France / Q000453:epidemiology; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D011247:Pregnancy; D011256:Pregnancy Outcome; D015995:Prevalence; D019851:Thrombophilia / Q000453:epidemiology* / Q000235:genetics
chemical_list: C095381:factor V Leiden; D005165:Factor V